Dr. Radomski is an Assistant Professor of Medicine and Clinical & Translational Science within the Division of General Internal Medicine at the University of Pittsburgh and Core Faculty with the VA Pittsburgh Healthcare System Center for Health Equity Research and Promotion. As a health services researcher, Dr. Radomski’s research focuses on developing and implementing patient-centered approaches to measure and reduce health service overuse. He is currently the principal investigator of a K23 Career Development Award from the National Institute on Aging and is also leading a major VA study to evaluate the use and cost of low-value health services received by Veterans in VA and non-VA care settings. His research has been published in journals such as JAMA, JAMA Internal Medicine, and Annals of Internal Medicine, and he is the recipient of the Award for Excellence in Clinician Investigation from the Society of General Internal Medicine Mid-Atlantic Region.
Apart from his research, he serves as the Assistant Director and Director of Academic Programs for the University of Pittsburgh’s Institute for Clinical Research Education and serves on the National Council of the Society of General Internal Medicine as Chair of the Board of Regional Leaders. He also maintains an outpatient general internal medicine practice and attends on the inpatient general medicine wards at UPMC Montefiore Hospital.
He resides in O’Hara Township with his wife, Brittany, and their two children: Derek and Audra. A proud undergraduate alumnus of Pitt and the Delta Chi Fraternity, Dr. Radomski enjoys following Pitt sports, trying out new restaurants, attending classical music concerts, and taking in the city by running in local races.
Education & Training
- BS (Molecular Biology & Political Science), University of Pittsburgh, 2006
- MD, Penn State University, 2010
- Internal Medicine Residency, University of Pittsburgh Medical Center, 2013
- Chief Medical Resident, University of Pittsburgh Medical Center, 2014
- General Internal Medicine/Clinical Research Fellowship, University of Pittsburgh Medical Center, 2016
- MS in Clinical Research, University of Pittsburgh, 2016
Oakes AH, Radmoski TR. Reducing low-value care and improving healthcare value. JAMA. 2021 May 4; 325(17):1715-1716.
In this paper, we describe a framework to reduce low value care focused on organizational behavioral change at the local health system level.
Radomski TR, Decker A, Khodyakov D, Thorpe CT, Hanlon JT, Roberts MS, Fine MJ, Gellad WF. Development of a metric to evaluate opportunities to decrease low-value prescribing in older adults. JAMA Network Open. 2022; 5(2):e2148599.
A panel of experts was convened using an online modified-Delphi approach to develop a scientifically valid and clinically useful low-value prescribing metric, entitled EVOLV-Rx (Evaluating Opportunities to Decrease Low-Value Prescribing).
Radmoski TR, Xinhua Z, Lovelace EZ, Sileanu FE, Rose L, Schwartz AL, Schleiden LJ, Oakes AH, Pickering AN, Yang D, Hale JA, Gellad WF, Fine MJ, Thorpe CT. Use and cost of low-value health services delivered or paid for by the Veterans Health Administration. JAMA Internal Medicine. 2022 Aug; 182(8):832-839.
In this cross-sectional study of 5.2 million enrolled Veterans, 19.6 low-value services per 100 Veterans were delivered by VA facilities or VA Community Care programs in fiscal year 2018, involving 13.6% of Veterans at a cost of $205.8 million. These findings suggest low-value use is common and costly among Veterans enrolled in VA, representing opportunities to reduce unnecessary health services delivered by VA facilities and VA Community Care programs.
Click here for a more complete bibliography of Dr. Radomski's works.
- Measuring the use, cost, and variation in the delivery of low-value health services
- The development and validation of a low-value prescribing metric in older adults (EVOLV-Rx)
- Electronic health record-based interventions to reduce low-value health services
- Describing the impact of dual health system use on health service utilization and outcomes
- Medication-based risk adjustment